Interim assessment in ALK-negative PTCL was characterized by higher positive and lower negative predictive values than in DLBCL [7], reflecting differences in the frequency of treatment failure [2]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.